Navigation Links
MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Date:3/11/2008

Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX releases CEO message #22
2. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
3. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
4. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
5. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
8. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. NeoStem to Present at Third Annual Stem Cell Summit in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
(Date:1/15/2014)... Raleigh, NC (PRWEB) January 15, 2014 ... enhancement to its Online Web Portal for Life Science organizations ... ability to specify the subject matter of their documents in ... This will help reduce time-to-delivery of translations, often a critical ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... N.J., July 24 Serious buyers and sellers of leading fine ... InformexUSA 2010 will experience even more focused, more efficient networking opportunities ... others in their specific market. , ... Francisco, with a new agenda to reflect a targeted, but separate, ...
... , , ... PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., today announced that ... to $10 million of the company,s newly issued 10% cumulative convertible preferred stock ... the company closed on the issuance of one million preferred shares for proceeds ...
... MUMBAI, July 24 , ... Focus 2009 Annual Executive,MindXchange on Biotechnology Applications in the Food ... The Indian food processing industry has seen some spectacular product,developments ... baby foods. A lot more has to be achieved through ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 2PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 3PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group 4Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan 2Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan 3Growing Awareness and Increased Investments Lead to Growth of Biotechnology Applications in the Food & Beverage and Dietary Supplements Sector, Reveals Frost & Sullivan 4
(Date:4/16/2014)... our movements, thoughts and feelings are the result of ... that some of the conversations might not be all that ... on, or even participating in, some of those discussions. But ... tuning in part of the time specifically, when the ...
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. Theoretical ... how these organisms should decide how best to preserve ... is quite adaptable. It moves about in liquids and ... can stick to an underlying substrate. Actually, the bacteria ...
(Date:4/16/2014)... Papatheodorou from the Institute of Experimental and Clinical Pharmacology and ... responsible for smuggling the toxin of the bacterium Clostridium ... formed by C. perfringens , a pathogen that causes ... the toxins of many other hospital germs of the genus ...
Breaking Biology News(10 mins):Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3Theoretical biophysics: Adventurous bacteria 2Gate for bacterial toxins found 2
... dry, barren prairie around Alberta,s Drumheller area was once ... a large inland sea, with loads of wetlands inhabited ... But that changed about 71-million-years ago, according to a ... in paleontology at the University of Calgary. The researchers, ...
... Deadliest Pathogens , Francisella tularensis , the cause ... existence, is considered a potential biological weapon because it is ... lethality in humans. While a live attenuated vaccine strain ... unable to understand the basis for its attenuated virulence. ...
... groups at Technische Universitt Mnchen (TUM) under Prof. Peter Schieberle ... studied four different edible fats and oils: Lard, butterfat, rapeseed ... the study participants ate 500 grams of low-fat yoghurt enriched ... as a supplement to their normal diet. "Olive ...
Cached Biology News:Dinosaur-era climate change study suggests reasons for turtle disappearance 2News tips from the journal mBio®, volume 4, issue 1 2Olive oil makes you feel full 2
... locking design in ice/water bath This ... number, created to easily match Cornings ... yet, please order under the old ... service for assistance. ID clarifier: rack ...
... Yeast Oligo Microarray Kit (V2), 2 ... simultaneously characterize expression of many thousands ... activity during important biological processes. Each ... 6,256 known ORFs from the S288C ...
... Kit (V2), 22K is useful for investigating plant ... microarray contains content derived from the ATH1 v. ... (TIGR) and represents 21,500 genes. ... 3? glass slides each containing an identical 22K ...
... software offers an intuitive, easy-to-use ... control, diverse data handling, and ... Comprehensive functions include data acquisition, ... management in both standalone and ...
Biology Products: